Enlivex (ENLV) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lakewood-Amedex Biotherapeutics is the larger company by market cap ($2.2 million vs $2.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | LABT |
|---|---|---|
| Share price | $1.05 | $0.2449 |
| Market cap | $2.01M | $2.19M |
| 1-day change | -11.76% | +15.03% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $7,904.00 | $-5.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.24B | — |
| 52-week high | $434.40 | $98.20 |
| 52-week low | $1.00 | $0.17 |
| Distance from 52-week high | -99.76% | -99.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +7519.05% | +4799.96% |
| Average volume | 73.14K | 16.14M |
| Shares outstanding | 1.91M | 8.95M |
| Employees | 34 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ENLV vs LABT FAQ
Which is bigger, Enlivex or Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics (LABT) is larger, with a market capitalization of $2.19M compared with $2.01M for Enlivex (ENLV).
Are Enlivex and Lakewood-Amedex Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.